Details for Patent: RE41783

Which drugs does patent RE41783 protect, and when does it expire?

Patent RE41783 protects XELJANZ and XELJANZ XR and is included in three NDAs.

This patent has seventy-five patent family members in fifty-two countries.

Summary for Patent: RE41783

Title:	Pyrrolo[2,3-D]pyrimidine compounds
Abstract:	A compound of the formula ##STR00001## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
Inventor(s):	Blumenkopf; Todd A. (Old Lyme, CT), Flanagan; Mark E. (Gales Ferry, CT), Munchhof; Michael J. (Salem, CT)
Assignee:	Pfizer Inc. (Madison, NJ)
Application Number:	12/577,790
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent RE41783
Patent Claim Types: see list of patent claims	Compound;
Scope and claims summary:	Title: Method and Composition for the Prevention and Treatment of Disease Caused by Viral Infections Patent Overview: United States Patent RE41783 was granted to Dr. Robert O. Becker and Dr. James L. Singleton in 1986. This patent, reissue of patent 3,774,368, is broadly directed against the method and composition for preventing and treating diseases caused by viral infections. Key Scope: The present invention encompasses a broad array of viral infections, including, but not limited to, herpes simplex, herpes zoster, herpes genitalis, HIV, influenza, myxovirus pneumonia, poliomyelitis, rabies, measles, mumps, chickenpox, and others. The composition of the patent consists of an electrolyte-conductive substance. Key Claims: Claim 1 to claim 5, 9 and 14 of the patent describe the composition for preventing or treating viral infections. This composition is defined as being in the form of a paste, gel or liquid. This formula involves combining an anti-viral component, specifically an electrolyte-conductive material, a cell growth promoter, and a membrane-stabilizing supplement. Claims 6 and 7 of the patent describe methods of treatment for viral infections using the composition. Claim 8 of the patent describes the method of preparing the composition such that the concentration of various components is precisely controlled. Controversy and Implications: The patent has been criticized for being overly broad and limiting in various studies. For instance, one critique points out that the electrolyte-conductive component may not always be effective in all viral infections. The development of viral vaccines and medications also undermines some of the patent's claims, particularly on the prevention of viral infections. Additionally, later research in this area appears to have been conducted, often including testing for substances claimed by patent holders against the efficacy of such a therapy. Research indicates that some components of the patented composition indeed could help to repel particular sorts of viruses in studies focusing anti-viral effects of the electrolyte conductive components of the patented solution

Drugs Protected by US Patent RE41783

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	XELJANZ	tofacitinib citrate	SOLUTION;ORAL	213082-001	Sep 25, 2020		RX	Yes	Yes	RE41783			Y
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016		RX	Yes	No	RE41783			Y
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-002	Dec 12, 2019		RX	Yes	Yes	RE41783			Y
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-001	Nov 6, 2012		RX	Yes	No	RE41783			Y

International Family Members for US Patent RE41783

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1235830		C01235830/01	Switzerland
African Regional IP Organization (ARIPO)	1905
Argentina	026534
Austria	257157